Brief: Rhythm Pharmaceuticals Announces FDA Acceptance For Priority Review Of Supplemental New Drug Application For Imcivree
26/08/2024 13:09
Aug 26 (Reuters) - Rhythm Pharmaceuticals Inc RYTM.O :
* RHYTHM PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE FOR
PRIORITY
REVIEW OF SUPPLEMENTAL NEW DRUG APPLICATION FOR IMCIVREE®
(SETMELANOTIDE) IN PATIENTS AS YOUNG AS 2 YEARS OLD
* RHYTHM PHARMACEUTICALS INC - FDA SETS PDUFA GOAL DATE OF
DECEMBER 26, 2024
Source text for Eikon: ID:nGNX488R56
Further company coverage: RYTM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rhythm Pharmaceuticals
See all newsBrief: Rhythm Pharmaceuticals Announces Appointment Of Manher (Aj) Joshi As Chief Medical Officer
Rhythm's drug shows promise for brain tumor-related weight condition in small study (updated)
Rhythm Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rhythm Pharma's obesity drug shows promise for brain tumor-related weight condition
Rhythm Pharmaceuticals Q2 net loss narrows on US launch demand